A Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib

被引：0
|
作者：
Chen, Y. [1 ]
Hei, Y. [1 ]
Yang, R. X. [1 ]
Kong, S. N. [1 ]
Zhang, H. M. [1 ]
机构：
[1] Air Force Mil Med Univ, Xijing Hosp, Xian, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
NSCLC; EGFR TKI; MET exon 14 skipping mutations;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-44
引用
收藏
页码：S658 / S658
页数：1
相关论文
共 20 条
  • [1] Synchronous Double Primary Lung Adenocarcinomas With EGFR L858R Point Mutation and MET Exon 14 Skipping Mutation
    Ando, Seijitsu
    Futami, Shinji
    Azuma, Koji
    Nishimatsu, Kanako
    Shirasaka, Takuma
    Minami, Seigo
    JOURNAL OF MEDICAL CASES, 2024, 15 (08) : 153 - 158
  • [2] Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer
    Hellyer, Jessica A.
    White, Maya N.
    Gardner, Rebecca M.
    Cunanan, Kristen
    Padda, Sukhmani K.
    Das, Millie
    Ramchandran, Kavitha
    Neal, Joel W.
    Wakelee, Heather A.
    CLINICAL LUNG CANCER, 2022, 23 (03) : 264 - 272
  • [3] Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
    Zhou, Jinhua
    Qin, Hongya
    Miao, Jianlong
    Liu, Ruijuan
    Wang, Wei
    MEDICINE, 2023, 102 (26) : E34110
  • [4] The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer
    Zhang, Yaxiong
    Chen, Gang
    Chen, Xi
    Fang, Wenfeng
    Gao, Fei
    Yang, Yunpeng
    Zhao, Yuanyuan
    Ma, Yuxiang
    Hong, Shaodong
    Zhang, Zhonghan
    Miao, Siyu
    Wu, Manli
    Huang, Xiaodan
    Luo, Youli
    Zhou, Cong
    Gong, Run
    Huang, Yan
    Chen, Likun
    Zhou, Ningning
    Zhao, Hongyun
    Zhang, Li
    JOURNAL OF CANCER, 2017, 8 (10): : 1865 - 1871
  • [5] Presence of MET exon 14 skipping and fusion as mechanism of osimertinb resistance in a lung adenocarcinoma with an EGFR exon 19 deletion that responds to combination of capmatinib and osimertinb: A case report
    Xiang, Siqi
    Zeng, Liang
    Xiang, Mingjun
    Zhang, Yongchang
    HELIYON, 2023, 9 (11)
  • [6] Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib
    Wang, Li
    Quan, Fei
    Guo, Zhen
    Lu, Zhongyu
    Yang, Duoxia
    Shi, Meiqi
    LUNG CANCER-TARGETS AND THERAPY, 2023, 14 : 79 - 84
  • [7] Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea
    Baek, Jin Ho
    Sun, Jong-Mu
    Min, Young Joo
    Cho, Eun Kyung
    Cho, Byoung Chul
    Kim, Joo-Hang
    Ahn, Myung-Ju
    Park, Keunchil
    LUNG CANCER, 2015, 87 (02) : 148 - 154
  • [8] Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation
    Gilardone, Sophia
    Thapa, Ram
    Laborde, Jose
    Shafique, Michael
    Saltos, Andreas
    Creelan, Ben
    Tanvetyanon, Tawee
    Chiappori, Alberto
    Simon, George
    Haura, Eric B.
    Gray, Jhanelle E.
    Chen, Dung-Tsa
    Melzer, Daniel
    Pellini, Bruna
    JOURNAL OF THORACIC DISEASE, 2023, 15 (11) : 6115 - +
  • [9] A Case Report of Primary Resistance to EGFR TKI in Lung Adenocarcinoma Due to Coexisting MET Exon 14 Skipping Mutation with Excellent Response to Combination of Gefitinib and Capmatinib
    Raut, Nirmal Vivek
    Srivastava, Siddharth
    Gangwani, Guarav Dilip
    Ali, Heena Sajid
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (02) : 204 - 207
  • [10] Investigation of the Efficacy of Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor in Patients With EGFR Exon 21 L858R Point Mutation-Positive Non-small Cell Lung Cancer
    Takahara, Yutaka
    Abe, Ryudai
    Nagae, Sumito
    Tanaka, Takuya
    Ishige, Yoko
    Shionoya, Ikuyo
    Yamamura, Kouichi
    Nojiri, Masafumi
    Iguchi, Masaharu
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
12